{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:54:48Z","timestamp":1794585288462,"version":"4.9.1"},"reference-count":126,"publisher":"Bentham Science Publishers Ltd.","issue":"26","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The IL-17 (interleukin 17) family consists of six structurally related pro-inflammatory\ncytokines, namely IL-17A to IL-17F. These cytokines have garnered significant scientific interest due to their\npivotal role in the pathogenesis of various diseases. Notably, a specific subset of T-cells expresses IL-17 family\nmembers, highlighting their importance in immune responses against microbial infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>IL-17 cytokines play a critical role in host defense mechanisms by inducing cytokines and chemokines,\nrecruiting neutrophils, modifying T-cell differentiation, and stimulating the production of antimicrobial\nproteins. Maintaining an appropriate balance of IL-17 is vital for overall health. However, dysregulated production\nof IL-17A and other members can lead to the pathogenesis of numerous inflammatory and autoimmune\ndiseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This review provides a comprehensive overview of the IL-17 family and its involvement in several\ninflammatory and autoimmune diseases. Relevant literature and research studies were analyzed to compile the\ndata presented in this review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>IL-17 cytokines, particularly IL-17A, have been implicated in the development of various inflammatory\nand autoimmune disorders, including multiple sclerosis, Hashimoto's thyroiditis, systemic lupus erythematosus,\npyoderma gangrenosum, autoimmune hepatic disorders, rheumatoid arthritis, psoriasis, psoriatic arthritis,\nankylosing spondylitis, osteoarthritis, and graft-versus-host disease. Understanding the role of IL-17 in these\ndiseases is crucial for developing targeted therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The significant involvement of IL-17 cytokines in inflammatory and autoimmune diseases underscores\ntheir potential as therapeutic targets. Current treatments utilizing antibodies against IL-17 cytokines and\nIL-17RA receptors have shown promise in managing these conditions. This review consolidates the understanding\nof IL-17 family members and their roles, providing valuable insights for the development of novel immunomodulators\nto effectively treat inflammatory and autoimmune diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1381612829666230904150808","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T01:48:50Z","timestamp":1693964930000},"page":"2078-2090","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Role of Th17 and IL-17 Cytokines on Inflammatory and Auto-immune Diseases"],"prefix":"10.2174","volume":"29","author":[{"given":"Saima","family":"Akhter","sequence":"first","affiliation":[{"name":"Department of Pharmacy, International Islamic University Chittagong, Chittagong 4318, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhin Muntaha","family":"Tasnim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, International Islamic University Chittagong, Chittagong 4318, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Nazmul","family":"Islam","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, International Islamic University Chittagong, Chittagong 4318, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdur","family":"Rauf","sequence":"additional","affiliation":[{"name":"Department of Chemistry,\nUniversity of Swabi, Swabi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saikat","family":"Mitra","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka, 1000, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha Bin","family":"Emran","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad A.","family":"Alhumaydhi","sequence":"additional","affiliation":[{"name":"Department of Medical\nLaboratories, College of Applied Medical Science, Qassim University, Buraydah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anees","family":"Ahmed Khalil","sequence":"additional","affiliation":[{"name":"University Institute of Diet and\nNutritionals Sciences, Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah S.M.","family":"Aljohani","sequence":"additional","affiliation":[{"name":"Department of Veterinary\nMedicine, College of Agriculture and Veterinary Medicine, Qassim University, Buraydah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Al Abdulmonem","sequence":"additional","affiliation":[{"name":"Department of Pathology,\nCollege of Medicine, Qassim University, Buraydah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthu","family":"Thiruvengadam","sequence":"additional","affiliation":[{"name":"Department of Crop Science, College of Sanghuh Life Science,\nKonkuk University, Seoul 05029, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1128\/IAI.01329-06","volume":"75","author":"Rudner X.L.","year":"2007","unstructured":"Rudner X.L.; Happel K.I.; Young E.A.; Shellito J.E.; Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect Immun 2007,75(6),3055-3061","journal-title":"Infect Immun"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1086\/422329","volume":"190","author":"Huang W.","year":"2004","unstructured":"Huang W.; Na L.; Fidel P.L.; Schwarzenberger P.; Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004,190(3),624-631","journal-title":"J Infect Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1365-2249.2005.02842.x","volume":"142","author":"Tipping P.G.","year":"2005","unstructured":"Tipping P.G.; Kitching A.R.; Glomerulonephritis, Th1 and Th2: what\u2019s new? Clin Exp Immunol 2005,142(2),207-215","journal-title":"Clin Exp Immunol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1681\/ASN.2010050536","volume":"22","author":"Kitching A.R.","year":"2011","unstructured":"Kitching A.R.; Holdsworth S.R.; The emergence of TH17 cells as effectors of renal injury. J Am Soc Nephrol 2011,22(2),235-238","journal-title":"J Am Soc Nephrol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.cyto.2015.07.029","volume":"77","author":"Ramani K.","year":"2016","unstructured":"Ramani K.; Biswas P.S.; Emerging roles of the Th17\/IL-17-axis in glomerulonephritis. Cytokine 2016,77,238-244","journal-title":"Cytokine"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ni1497","volume":"8","author":"Wilson N.J.","year":"2007","unstructured":"Wilson N.J.; Boniface K.; Chan J.R.; Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007,8(9),950-957","journal-title":"Nat Immunol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nri2295","volume":"8","author":"Dong C.","year":"2008","unstructured":"Dong C.; TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008,8(5),337-348","journal-title":"Nat Rev Immunol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","volume":"27","author":"Korn T.","year":"2009","unstructured":"Korn T.; Bettelli E.; Oukka M.; Kuchroo V.K.; IL-17 and Th17 cells. Annu Rev Immunol 2009,27(1),485-517","journal-title":"Annu Rev Immunol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.cell.2010.02.021","volume":"140","author":"Littman D.R.","year":"2010","unstructured":"Littman D.R.; Rudensky A.Y.; Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010,140(6),845-858","journal-title":"Cell"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","volume":"13","author":"Noack M.","year":"2014","unstructured":"Noack M.; Miossec P.; Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014,13(6),668-677","journal-title":"Autoimmun Rev"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1056\/NEJMra0707449","volume":"361","author":"Miossec P.","year":"2009","unstructured":"Miossec P.; Korn T.; Kuchroo V.K.; Interleukin-17 and type 17 helper T cells. N Engl J Med 2009,361(9),888-898","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/eji.201242605","volume":"42","author":"Cypowyj S.","year":"2012","unstructured":"Cypowyj S.; Picard C.; Mar\u00f3di L, Casanova JL, Puel A. Immunity to infection in IL-17-deficient mice and humans. Eur J Immunol 2012,42(9),2246-2254","journal-title":"Eur J Immunol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrd3794","volume":"11","author":"Miossec P.","year":"2012","unstructured":"Miossec P.; Kolls J.K.; Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012,11(10),763-776","journal-title":"Nat Rev Drug Discov"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","volume":"129","author":"Onishi R.M.","year":"2010","unstructured":"Onishi R.M.; Gaffen S.L.; Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010,129(3),311-321","journal-title":"Immunology"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nri2800","volume":"10","author":"Cua D.J.","year":"2010","unstructured":"Cua D.J.; Tato C.M.; Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010,10(7),479-489","journal-title":"Nat Rev Immunol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"Gaffen S.L.","year":"2014","unstructured":"Gaffen S.L.; Jain R.; Garg A.V.; Cua D.J.; The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 2014,14(9),585-600","journal-title":"Nat Rev Immunol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/art.33507","volume":"64","author":"Kenna T.J.","year":"2012","unstructured":"Kenna T.J.; Davidson S.I.; Duan R.; Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis. Arthritis Rheum 2012,64(5),1420-1429","journal-title":"Arthritis Rheum"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.molmed.2016.01.001","volume":"22","author":"Beringer A.","year":"2016","unstructured":"Beringer A.; Noack M.; Miossec P.; IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med 2016,22(3),230-241","journal-title":"Trends Mol Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.gene.2018.10.038","volume":"686","author":"Dong C.","year":"2019","unstructured":"Dong C.; Kong S.; Zheng X.; Genome-wide identification of interleukin-17 (IL17) in common carp (Cyprinus carpio) and its expression following Aeromonas hydrophila infection. Gene 2019,686,68-75","journal-title":"Gene"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1164\/rccm.200711-1648OC","volume":"178","author":"Mauermann N.","year":"2008","unstructured":"Mauermann N.; Burian J.; von Garnier C.; Interferon-\u03b3 regulates idiopathic pneumonia syndrome, a Th17+CD4+ T-cell-mediated graft-versus-host disease. Am J Respir Crit Care Med 2008,178(4),379-388","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","volume":"9","author":"Brembilla N.C.","year":"2018","unstructured":"Brembilla N.C.; Senra L.; Boehncke W.H.; The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol 2018,9,1682","journal-title":"Front Immunol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1359-6101(03)00002-9","volume":"14","author":"Moseley T.A.","year":"2003","unstructured":"Moseley T.A.; Haudenschild D.R.; Rose L.; Reddi A.H.; Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003,14(2),155-174","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.immuni.2011.02.012","volume":"34","author":"Iwakura Y.","year":"2011","unstructured":"Iwakura Y.; Ishigame H.; Saijo S.; Nakae S.; Functional specialization of interleukin-17 family members. Immunity 2011,34(2),149-162","journal-title":"Immunity"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.fsi.2015.09.020","volume":"47","author":"Chi H.","year":"2015","unstructured":"Chi H.; Sun L.; Comparative study of four interleukin 17 cytokines of tongue sole Cynoglossus semilaevis: Genomic structure, expression pattern, and promoter activity. Fish Shellfish Immunol 2015,47(1),321-330","journal-title":"Fish Shellfish Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.fsi.2017.08.010","volume":"69","author":"Jiang B.","year":"2017","unstructured":"Jiang B.; Li Y.W.; Hu Y.Z.; Luo H.L.; Li A.X.; Characterization and expression analysis of six interleukin-17 receptor genes in grouper (Epinephelus coioides) after Cryptocaryon irritans infection. Fish Shellfish Immunol 2017,69,46-51","journal-title":"Fish Shellfish Immunol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.3390\/ijms21072439","volume":"21","year":"2020","unstructured":"Gonz\u00e1lez-Fern\u00e1ndez C Chaves-Pozo E, Cuesta A. Identification and regulation of interleukin-17 (IL-17) family ligands in the teleost fish European sea bass. Int J Mol Sci 2020,21(7),2439","journal-title":"Int J Mol Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"103731","DOI":"10.1016\/j.dci.2020.103731","volume":"110","author":"Mao X.","year":"2020","unstructured":"Mao X.; Tian Y.; Wen H.; Effects of Vibrio harveyi infection on serum biochemical parameters and expression profiles of interleukin-17 (IL-17)\/interleukin-17 receptor (IL-17R) genes in spotted sea bass. Dev Comp Immunol 2020,110,103731","journal-title":"Dev Comp Immunol"},{"key":"ref=28","first-page":"805","volume":"11","author":"Bordon Y.","year":"2011","unstructured":"Bordon Y.; Cytokines: IL-17C joins the family firm. Nat Rev Immunol 2011,11(12),805","journal-title":"Nat Rev Immunol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1084\/jem.20080321","volume":"205","author":"de Beaucoudrey L.","year":"2008","unstructured":"de Beaucoudrey L.; Puel A.; Filipe-Santos O.; Mutations in STAT3 and IL12RB1 impair the development of human IL-17\u2013producing T cells. J Exp Med 2008,205(7),1543-1550","journal-title":"J Exp Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1126\/science.1200439","volume":"332","author":"Puel A.","year":"2011","unstructured":"Puel A.; Cypowyj S.; Bustamante J.; Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011,332(6025),65-68","journal-title":"Science"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cyto.2013.03.014","volume":"62","author":"Song X.","year":"2013","unstructured":"Song X.; Qian Y.; The activation and regulation of IL-17 receptor mediated signaling. Cytokine 2013,62(2),175-182","journal-title":"Cytokine"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.4049\/jimmunol.179.8.5462","volume":"179","author":"Kuestner R.E.","year":"2007","unstructured":"Kuestner R.E.; Taft D.W.; Haran A.; Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol 2007,179(8),5462-5473","journal-title":"J Immunol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2147\/JIR.S278335","volume":"13","author":"Shibabaw T.","year":"2020","unstructured":"Shibabaw T.; Inflammatory cytokine: IL-17A signaling pathway in patients present with COVID-19 and current treatment strategy. J Inflamm Res 2020,13,673-680","journal-title":"J Inflamm Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.cellsig.2013.07.021","volume":"25","author":"Song X.","year":"2013","unstructured":"Song X.; Qian Y.; IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases. Cell Signal 2013,25(12),2335-2347","journal-title":"Cell Signal"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.cellsig.2010.11.022","volume":"23","author":"Chang S.H.","year":"2011","unstructured":"Chang S.H.; Dong C.; Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal 2011,23(7),1069-1075","journal-title":"Cell Signal"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/ncomms2880","volume":"4","author":"Liu S.","year":"2013","unstructured":"Liu S.; Song X.; Chrunyk B.A.; Crystal structures of interleukin 17A and its complex with IL-17 receptor A. Nat Commun 2013,4(1),1888","journal-title":"Nat Commun"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/imm.12142","volume":"141","author":"Kirkham B.W.","year":"2014","unstructured":"Kirkham B.W.; Kavanaugh A.; Reich K.; Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology 2014,141(2),133-142","journal-title":"Immunology"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.4049\/jimmunol.1001153","volume":"185","author":"Kagami S.","year":"2010","unstructured":"Kagami S.; Rizzo H.L.; Kurtz S.E.; Miller L.S.; Blauvelt A.; IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol 2010,185(9),5453-5462","journal-title":"J Immunol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.molimm.2017.07.004","volume":"90","author":"Bie Q.","year":"2017","unstructured":"Bie Q.; Jin C.; Zhang B.; Dong H.; IL-17B: A new area of study in the IL-17 family. Mol Immunol 2017,90,50-56","journal-title":"Mol Immunol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"7128","DOI":"10.4049\/jimmunol.179.10.7128","volume":"179","author":"Yamaguchi Y.","year":"2007","unstructured":"Yamaguchi Y.; Fujio K.; Shoda H.; IL-17B and IL-17C are associated with TNF-\u03b1 production and contribute to the exacerbation of inflammatory arthritis. J Immunol 2007,179(10),7128-7136","journal-title":"J Immunol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.immuni.2015.03.008","volume":"42","author":"Reynolds J.M.","year":"2015","unstructured":"Reynolds J.M.; Lee Y.H.; Shi Y.; Interleukin-17B antagonizes interleukin-25-mediated mucosal inflammation. Immunity 2015,42(4),692-703","journal-title":"Immunity"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"18914","DOI":"10.18632\/oncotarget.14835","volume":"8","author":"Bie Q.","year":"2017","unstructured":"Bie Q.; Zhang B.; Sun C.; IL-17B activated mesenchymal stem cells enhance proliferation and migration of gastric cancer cells. Oncotarget 2017,8(12),18914-18923","journal-title":"Oncotarget"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.canlet.2018.02.037","volume":"422","author":"Yang Y.F.","year":"2018","unstructured":"Yang Y.F.; Lee Y.C.; Lo S.; A positive feedback loop of IL-17B-IL-17RB activates ERK\/\u03b2-catenin to promote lung cancer metastasis. Cancer Lett 2018,422,44-55","journal-title":"Cancer Lett"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"113360","DOI":"10.18632\/oncotarget.23008","volume":"8","author":"Laprevotte E.","year":"2017","unstructured":"Laprevotte E.; Cochaud S.; du Manoir S.; The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1\/2 pathway. Oncotarget 2017,8(69),113360-113372","journal-title":"Oncotarget"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1084\/jem.20141702","volume":"212","author":"Wu H.H.","year":"2015","unstructured":"Wu H.H.; Hwang-Verslues W.W.; Lee W.H.; Targeting IL-17B\u2013IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. J Exp Med 2015,212(3),333-349","journal-title":"J Exp Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1084\/jem.20160581","volume":"214","author":"Peng T.","year":"2017","unstructured":"Peng T.; Chanthaphavong R.S.; Sun S.; Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation. J Exp Med 2017,214(8),2315-2329","journal-title":"J Exp Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.immuni.2011.09.010","volume":"35","author":"Chang S.H.","year":"2011","unstructured":"Chang S.H.; Reynolds J.M.; Pappu B.P.; Chen G.; Martinez G.J.; Dong C.; Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 2011,35(4),611-621","journal-title":"Immunity"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/ni.2155","volume":"12","author":"Song X.","year":"2011","unstructured":"Song X.; Zhu S.; Shi P.; IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol 2011,12(12),1151-1158","journal-title":"Nat Immunol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/ni.2156","volume":"12","author":"Ramirez-Carrozzi V.","year":"2011","unstructured":"Ramirez-Carrozzi V.; Sambandam A.; Luis E.; IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol 2011,12(12),1159-1166","journal-title":"Nat Immunol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/ncomms2127","volume":"3","author":"Mellett M.","year":"2012","unstructured":"Mellett M.; Atzei P.; Horgan A.; Orphan receptor IL-17RD tunes IL-17A signalling and is required for neutrophilia. Nat Commun 2012,3(1),1119","journal-title":"Nat Commun"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.clim.2013.10.001","volume":"149","author":"Li D.","year":"2013","unstructured":"Li D.; Cai W.; Gu R.; Th17 cell plays a role in the pathogenesis of Hashimoto\u2019s thyroiditis in patients. Clin Immunol 2013,149(3),411-420","journal-title":"Clin Immunol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.1038\/ncomms7669","volume":"6","author":"Mellett M.","year":"2015","unstructured":"Mellett M.; Atzei P.; Bergin R.; Orphan receptor IL-17RD regulates Toll-like receptor signalling via SEFIR\/TIR interactions. Nat Commun 2015,6(1),6669-6683","journal-title":"Nat Commun"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1074\/jbc.M114.586560","volume":"290","author":"Yang S.","year":"2015","unstructured":"Yang S.; Wang Y.; Mei K.; Tumor necrosis factor receptor 2 (TNFR2) interleukin-17 receptor D (IL-17RD) heteromerization reveals a novel mechanism for NF-\u03baB activation. J Biol Chem 2015,290(2),861-871","journal-title":"J Biol Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.celrep.2016.07.075","volume":"16","author":"Saddawi-Konefka R.","year":"2016","unstructured":"Saddawi-Konefka R.; Seelige R.; Gross E.T.E.; Nrf2 induces IL-17D to mediate tumor and virus surveillance. Cell Rep 2016,16(9),2348-2358","journal-title":"Cell Rep"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cytogfr.2010.10.002","volume":"21","author":"Reynolds J.M.","year":"2010","unstructured":"Reynolds J.M.; Angkasekwinai P.; Dong C.; IL-17 family member cytokines: Regulation and function in innate immunity. Cytokine Growth Factor Rev 2010,21(6),413-423","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.0300-9475.2004.01443.x","volume":"60","author":"Gratchev A.","year":"2004","unstructured":"Gratchev A.; Kzhyshkowska J.; Duperrier K.; Utikal J.; Velten F.W.; Goerdt S.; The receptor for interleukin-17E is induced by Th2 cytokines in antigen-presenting cells. Scand J Immunol 2004,60(3),233-237","journal-title":"Scand J Immunol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4049\/jimmunol.169.1.443","volume":"169","author":"Hurst S.D.","year":"2002","unstructured":"Hurst S.D.; Muchamuel T.; Gorman D.M.; New IL-17 family members promote Th1 or Th2 responses in the lung: In vivo function of the novel cytokine IL-25. J Immunol 2002,169(1),443-453","journal-title":"J Immunol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1084\/jem.20061738","volume":"204","author":"Kleinschek M.A.","year":"2007","unstructured":"Kleinschek M.A.; Owyang A.M.; Joyce-Shaikh B.; IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med 2007,204(1),161-170","journal-title":"J Exp Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nature08636","volume":"463","author":"Moro K.","year":"2010","unstructured":"Moro K.; Yamada T.; Tanabe M.; Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells. Nature 2010,463(7280),540-544","journal-title":"Nature"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"256ra134","DOI":"10.1126\/scitranslmed.3009124","volume":"6","author":"Beale J.","year":"2014","unstructured":"Beale J.; Jayaraman A.; Jackson D.J.; Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci Transl Med 2014,6(256),256ra134","journal-title":"Sci Transl Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaci.2018.03.019","volume":"142","author":"Kohanski M.A.","year":"2018","unstructured":"Kohanski M.A.; Workman A.D.; Patel N.N.; Solitary chemosensory cells are a primary epithelial source of IL-25 in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2018,142(2),460-469.e7","journal-title":"J Allergy Clin Immunol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.1074\/jbc.C600322200","volume":"282","author":"Akimzhanov A.M.","year":"2007","unstructured":"Akimzhanov A.M.; Yang X.O.; Dong C.; Chromatin remodeling of interleukin-17 (IL-17)-IL-17F cytokine gene locus during inflammatory helper T cell differentiation. J Biol Chem 2007,282(9),5969-5972","journal-title":"J Biol Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.4049\/jimmunol.179.6.4135","volume":"179","author":"Hartupee J.","year":"2007","unstructured":"Hartupee J.; Liu C.; Novotny M.; Li X.; Hamilton T.; IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol 2007,179(6),4135-4141","journal-title":"J Immunol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/B978-0-12-812630-1.00014-1","author":"Piper C.","year":"2019","unstructured":"Piper C.; Drobyski W.R.;  Role of TH17 cells and interleukin 17 in graft-versus-host disease and graft versus leukemia reactivity 2019,231-249","journal-title":"Role of TH17 cells and interleukin 17 in graft-versus-host disease and graft versus leukemia reactivity"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/0300060513501751","volume":"42","author":"Chen B.","year":"2014","unstructured":"Chen B.; Deng Y.; Tan Y.; Qin J.; Chen L.B.; Association between severity of knee osteoarthritis and serum and synovial fluid interleukin 17 concentrations. J Int Med Res 2014,42(1),138-144","journal-title":"J Int Med Res"},{"key":"ref=66","first-page":"627","volume":"47","author":"Paw\u0142owska J.","year":"2009","unstructured":"Paw\u0142owska J.; Mikosik A; Soroczynska-Cybula M,; Different distribution of CD4 and CD8 T cells in synovial membrane and peripheral blood of rheumatoid arthritis and osteoarthritis patients. Folia Histochem Cytobiol 2009,47(4),627-32","journal-title":"Folia Histochem Cytobiol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s13075-015-0847-3","volume":"17","author":"Suurmond J.","year":"2015","unstructured":"Suurmond J.; Dorj\u00e9e A.L.; Boon M.R.; Retraction Note: Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther 2015,17(1),354","journal-title":"Arthritis Res Ther"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.joca.2005.10.004","volume":"14","author":"Honorati M.C.","year":"2006","unstructured":"Honorati M.C.; Neri S.; Cattini L.; Facchini A.; Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage 2006,14(4),345-352","journal-title":"Osteoarthritis Cartilage"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1053\/joca.2002.0829","volume":"10","author":"Honorati M.C.","year":"2002","unstructured":"Honorati M.C.; Bovara M.; Cattini L.; Piacentini A.; Facchini A.; Contribution of interleukin 17 to human cartilage degradation and synovial inflammation in osteoarthritis. Osteoarthritis Cartilage 2002,10(10),799-807","journal-title":"Osteoarthritis Cartilage"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","volume":"160","author":"Johansen C.","year":"2009","unstructured":"Johansen C.; Usher P.A.; Kjellerup R.B.; Lundsgaard D.; Iversen L.; Kragballe K.; Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 2009,160(2),319-324","journal-title":"Br J Dermatol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4103\/0019-5154.62752","volume":"55","author":"Raychaudhuri S.","year":"2010","unstructured":"Raychaudhuri S.; Raychaudhuri S.; Scid mouse model of psoriasis: A unique tool for drug development of autoreactive T-cell and TH-17 cell-mediated autoimmune diseases. Indian J Dermatol 2010,55(2),157-160","journal-title":"Indian J Dermatol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","volume":"359","author":"Raychaudhuri S.P.","year":"2012","unstructured":"Raychaudhuri S.P.; Raychaudhuri S.K.; Genovese M.C.; IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 2012,359(1-2),419-429","journal-title":"Mol Cell Biochem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/art.38376","volume":"66","author":"Menon B.","year":"2014","unstructured":"Menon B.; Gullick N.J.; Walter G.J.; Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol 2014,66(5),1272-1281","journal-title":"Arthritis Rheumatol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.21749","volume":"54","author":"Kirkham B.W.","year":"2006","unstructured":"Kirkham B.W.; Lassere M.N.; Edmonds J.P.; Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: A two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006,54(4),1122-1131","journal-title":"Arthritis Rheum"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/B978-0-12-398270-4.00030-6","author":"Schaeffer J.","year":"2015","unstructured":"Schaeffer J.; Cossetti C.; Mallucci G.; Pluchino S.; Chapter 30-Multiple sclerosis. Neurobiology of brain disorders 2015,497-520","journal-title":"Neurobiology of brain disorders"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2353\/ajpath.2008.070690","volume":"172","author":"Tzartos J.S.","year":"2008","unstructured":"Tzartos J.S.; Friese M.A.; Craner M.J.; Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008,172(1),146-155","journal-title":"Am J Pathol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1096\/fj.09-141978","volume":"24","author":"Huppert J.","year":"2010","unstructured":"Huppert J.; Closhen D.; Croxford A.; Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J 2010,24(4),1023-1034","journal-title":"FASEB J"},{"key":"ref=78","first-page":"89","volume":"18","author":"Bossowski A","year":"2012","unstructured":"Bossowski A; Moniuszko M; Id\u017akowska E; Analiza kom\u00f3rek CD4+CD161+CD196+ i CD4+IL-17+ Th17 we krwi obwodowej u m\u0142odocianych z zapaleniem tarczycy typu Hashimoto i chorob\u0105 Gravesa-Basedowa. Pediatr Endocrinol Diabetes Metab 2012,18(3),89-95","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1080\/08916934.2016.1183654","volume":"49","author":"Bossowski A","year":"2016","unstructured":"Bossowski A; Moniuszko M; Id\u017akowska E; Decreased proportions of CD4 + IL17+\/CD4 + CD25 + CD127\u2212 and CD4 + IL17+\/CD4 + CD25 + CD127 \u2212 FoxP3+ T cells in children with autoimmune thyroid diseases. Autoimmunity 2016,49(5),320-328","journal-title":"Autoimmunity"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2042018820907013","author":"El-Zawawy H.T.","year":"2020","unstructured":"El-Zawawy H.T.; Farag H.F.; Tolba M.M.; Abdalsamea H.A.; Improving Hashimoto\u2019s thyroiditis by eradicating Blastocystis hominis: relation to IL-17. Ther Adv Endocrinol Metab 2020,11","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/toxsci\/kfy019","volume":"163","author":"Duan J.","year":"2018","unstructured":"Duan J.; Kang J.; Deng T.; Yang X.; Chen M.; Exposure to DBP and high iodine aggravates autoimmune thyroid disease through increasing the levels of IL-17 and thyroid-binding globulin in Wistar rats. Toxicol Sci 2018,163(1),196-205","journal-title":"Toxicol Sci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"551","DOI":"10.4103\/ijem.IJEM_412_16","volume":"21","author":"Jadali Z.","year":"2017","unstructured":"Jadali Z.; Esfahanian F.; Ghelich R.; Rashidian H.; Increased levels of serum interleukin-17 in patients with Hashimoto\u2019s thyroiditis. Indian J Endocrinol Metab 2017,21(4),551-554","journal-title":"Indian J Endocrinol Metab"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1002\/eji.201141751","volume":"41","author":"Simoni Y.","year":"2011","unstructured":"Simoni Y.; Gautron A.S.; Beaudoin L.; NOD mice contain an elevated frequency of iNKT17 cells that exacerbate diabetes. Eur J Immunol 2011,41(12),3574-3585","journal-title":"Eur J Immunol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.4049\/jimmunol.0902822","volume":"184","author":"Nikoopour E.","year":"2010","unstructured":"Nikoopour E.; Schwartz J.A.; Huszarik K.; Th17 polarized cells from nonobese diabetic mice following mycobacterial adjuvant immunotherapy delay type 1 diabetes. J Immunol 2010,184(9),4779-4788","journal-title":"J Immunol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.4049\/jimmunol.1001860","volume":"185","author":"Marwaha A.K.","year":"2010","unstructured":"Marwaha A.K.; Crome S.Q.; Panagiotopoulos C.; Cutting edge: Increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Immunol 2010,185(7),3814-3818","journal-title":"J Immunol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jhep.2018.12.035","volume":"70","author":"Schmidt T.","year":"2019","unstructured":"Schmidt T.; Schwinge D.; Rolvien T.; Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis. J Hepatol 2019,70(5),941-953","journal-title":"J Hepatol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11914-009-0004-5","volume":"7","author":"Miller P.D.","year":"2009","unstructured":"Miller P.D.; Denosumab: Anti-RANKL antibody. Curr Osteoporos Rep 2009,7(1),18-22","journal-title":"Curr Osteoporos Rep"},{"key":"ref=88","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.27.20202762","author":"Vaillant A.J.","year":"2020","unstructured":"Vaillant A.J.; Akpaka P.E.; Cytokines (IL-17, IL-23 and IL-33) in systemic lupus erythematosus in Trinidad and Tobago. medRxiv 2020","journal-title":"medRxiv"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bjd.16050","volume":"178","author":"Papp K.A.","year":"2018","unstructured":"Papp K.A.; Leonardi C.L.; Blauvelt A.; Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol 2018,178(3),674-681","journal-title":"Br J Dermatol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.clim.2008.01.019","volume":"127","author":"Wong C.K.","year":"2008","unstructured":"Wong C.K.; Lit L.C.W.; Tam L.S.; Li E.K.M.; Wong P.T.Y.; Lam C.W.K.; Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008,127(3),385-393","journal-title":"Clin Immunol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejim.2010.03.004","volume":"21","author":"Tanasescu C.","year":"2010","unstructured":"Tanasescu C.; Balanescu E.; Balanescu P.; IL-17 in cutaneous lupus erythematosus. Eur J Intern Med 2010,21(3),202-207","journal-title":"Eur J Intern Med"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s40744-021-00380-2","volume":"8","author":"van der Horst-Bruinsma I.","year":"2021","unstructured":"van der Horst-Bruinsma I.; Miceli-Richard C.; Braun J.; A pooled analysis reporting the efficacy and safety of secukinumab in male and female patients with ankylosing spondylitis. Rheumatol Ther 2021,8(4),1775-1787","journal-title":"Rheumatol Ther"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3899\/jrheum.201111","volume":"48","author":"Schett G.","year":"2021","unstructured":"Schett G.; Baraliakos X.; Van den Bosch F.; Secukinumab efficacy on enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal phase III studies. J Rheumatol 2021,48(8),1251-1258","journal-title":"J Rheumatol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40744-020-00269-6","volume":"8","author":"Baraliakos X.","year":"2021","unstructured":"Baraliakos X.; Van den Bosch F.; Machado P.M.; Achievement of remission endpoints with secukinumab over 3 years in active ankylosing spondylitis: pooled analysis of two phase 3 studies. Rheumatol Ther 2021,8(1),273-288","journal-title":"Rheumatol Ther"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"e000749","DOI":"10.1136\/rmdopen-2018-000749","volume":"4","author":"Braun J.","year":"2018","unstructured":"Braun J.; Deodhar A.; Landew\u00e9 R.; Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. RMD Open 2018,4(2),e000749","journal-title":"RMD Open"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/acr2.11139","volume":"2","author":"Deodhar A.A.","year":"2020","unstructured":"Deodhar A.A.; Miceli-Richard C.; Baraliakos X.; Incidence of uveitis in secukinumab\u2010treated patients with ankylosing spondylitis: pooled data analysis from three phase 3 studies. ACR Open Rheumatol 2020,2(5),294-299","journal-title":"ACR Open Rheumatol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/1756-185X.13094","volume":"20","author":"Wei J.C.C.","year":"2017","unstructured":"Wei J.C.C.; Baeten D.; Sieper J.; Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies. Int J Rheum Dis 2017,20(5),589-596","journal-title":"Int J Rheum Dis"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/00207454.2016.1231186","volume":"127","author":"Kharwar N.K.","year":"2017","unstructured":"Kharwar N.K.; Prasad K.N.; Singh K.; Paliwal V.K.; Modi D.R.; Polymorphisms of IL-17 and ICAM-1 and their expression in Guillain-Barr\u00e9 syndrome. Int J Neurosci 2017,127(8),680-687","journal-title":"Int J Neurosci"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/260473","volume":"2012","author":"Li S.","year":"2012","unstructured":"Li S.; Yu M.; Li H.; Zhang H.; Jiang Y.; IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barr\u00e9 syndrome. Mediators Inflamm 2012,2012,1-7","journal-title":"Mediators Inflamm"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/1744666X.2018.1438269","volume":"14","author":"Ahn C.","year":"2018","unstructured":"Ahn C.; Negus D.; Huang W.; Pyoderma gangrenosum: A review of pathogenesis and treatment. Expert Rev Clin Immunol 2018,14(3),225-233","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/iwj.13389","volume":"17","author":"Hobbs M.M.","year":"2020","unstructured":"Hobbs M.M.; Ortega-Loayza A.G.; Pyoderma gangrenosum: From historical perspectives to emerging investigations. Int Wound J 2020,17(5),1255-1265","journal-title":"Int Wound J"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/bjd.15226","volume":"176","author":"Marzano A.V.","year":"2017","unstructured":"Marzano A.V.; Damiani G.; Ceccherini I.; Berti E.; Gattorno M.; Cugno M.; Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol 2017,176(6),1588-1598","journal-title":"Br J Dermatol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jdcr.2020.08.033","volume":"6","author":"Tee M.W.","year":"2020","unstructured":"Tee M.W.; Avarbock A.B.; Ungar J.; Frew J.W.; Rapid resolution of pyoderma gangrenosum with brodalumab therapy. JAAD Case Rep 2020,6(11),1167-1169","journal-title":"JAAD Case Rep"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","volume":"83","author":"Frew J.W.","year":"2020","unstructured":"Frew J.W.; Navrazhina K.; Grand D.; The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study. J Am Acad Dermatol 2020,83(5),1341-1348","journal-title":"J Am Acad Dermatol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"e18909","DOI":"10.1371\/journal.pone.0018909","volume":"6","author":"Zhao L.","year":"2011","unstructured":"Zhao L.; Tang Y.; You Z.; Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One 2011,6(4),e18909","journal-title":"PLoS One"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/icb.2011.59","volume":"90","author":"Yan S.","year":"2012","unstructured":"Yan S.; Wang L.; Liu N.; Wang Y.; Chu Y.; Critical role of interleukin\u201017\/interleukin\u201017 receptor axis in mediating Con A\u2010induced hepatitis. Immunol Cell Biol 2012,90(4),421-428","journal-title":"Immunol Cell Biol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1002\/jbmr.2228","volume":"29","author":"Tyagi A.M.","year":"2014","unstructured":"Tyagi A.M.; Mansoori M.N.; Srivastava K.; Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-\u03b1 antibodies. J Bone Miner Res 2014,29(9),1981-1992","journal-title":"J Bone Miner Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3899\/jrheum.150182","volume":"43","author":"Mease P.J.","year":"2016","unstructured":"Mease P.J.; Genovese M.C.; Mutebi A.; Improvement in psoriasis signs and symptoms assessed by the Psoriasis Symptom Inventory with brodalumab treatment in patients with psoriatic arthritis. J Rheumatol 2016,43(2),343-349","journal-title":"J Rheumatol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","volume":"397","author":"Papp K.A.","year":"2021","unstructured":"Papp K.A.; Weinberg M.A.; Morris A.; Reich K.; IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet 2021,397(10284),1564-1575","journal-title":"Lancet"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/jdv.17071","volume":"35","author":"Kaul M.","year":"2021","unstructured":"Kaul M.; Jarvis P.; Rozenberg I.; First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol 2021,35(5),1143-1151","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1002\/eji.200636658","volume":"36","author":"R\u00f6hn TA","year":"2006","unstructured":"R\u00f6hn TA; Jennings GT; Hernandez M; Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 2006,36(11),2857-67","journal-title":"Eur J Immunol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1002\/eji.200636484","volume":"36","author":"Sonderegger I","year":"2006","unstructured":"Sonderegger I; R\u00f6hn TA; Kurrer MO; Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol 2006,36(11),2849-2856","journal-title":"Eur J Immunol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1182\/blood-2012-02-412726","volume":"120","author":"Gelderblom M.","year":"2012","unstructured":"Gelderblom M.; Weymar A.; Bernreuther C.; Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood 2012,120(18),3793-3802","journal-title":"Blood"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1111\/jdv.12996","volume":"29","author":"Langley R.G.","year":"2015","unstructured":"Langley R.G.; Rich P.; Menter A.; Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2015,29(9),1763-1770","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/jdv.14237","volume":"31","author":"Menter A.","year":"2017","unstructured":"Menter A.; Warren R.B.; Langley R.G.; Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol 2017,31(10),1686-1692","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1002\/art.38617","volume":"66","author":"Genovese M.C.","year":"2014","unstructured":"Genovese M.C.; Greenwald M.; Cho C.S.; A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 2014,66(7),1693-1704","journal-title":"Arthritis Rheumatol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3899\/jrheum.140831","volume":"43","author":"Genovese M.C.","year":"2016","unstructured":"Genovese M.C.; Braun D.K.; Erickson J.S.; Safety and efficacy of open-label subcutaneous ixekizumab treatment for 48 weeks in a phase II study in biologic-naive and TNF-IR patients with rheumatoid arthritis. J Rheumatol 2016,43(2),289-297","journal-title":"J Rheumatol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","volume":"2","author":"Hueber W.","year":"2010","unstructured":"Hueber W.; Patel D.D.; Dryja T.; Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010,2(52),52ra72","journal-title":"Sci Transl Med"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/rheumatology\/kev258","volume":"55","author":"Burmester G.R.","year":"2016","unstructured":"Burmester G.R.; Durez P.; Shestakova G.; Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. Rheumatology (Oxford) 2016,55(1),49-55","journal-title":"Rheumatology (Oxford)"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"OA2897","DOI":"10.1183\/1393003.congress-2017.OA2897","volume":"50","author":"Khokhlovich E.","year":"2017","unstructured":"Khokhlovich E.; Grant S.; Kazani S.; Late Breaking Abstract - The biological pathways underlying response to anti-IL-17A (AIN457; secukinumab) therapy differ across severe asthmatic patients. Eur Respir J 2017,50,OA2897","journal-title":"Eur Respir J"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","volume":"122","author":"Letko E.","year":"2015","unstructured":"Letko E.; Yeh S.; Foster C.S.; Pleyer U.; Brigell M.; Grosskreutz C.L.; Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology 2015,122(5),939-948","journal-title":"Ophthalmology"},{"key":"ref=122","first-page":"27","volume":"38","author":"Erdes S.","year":"2020","unstructured":"Erdes S.; Nasonov E.; Kunder E.; Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clin Exp Rheumatol 2020,38(1),27-34","journal-title":"Clin Exp Rheumatol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s13555-021-00554-4","volume":"11","author":"Puig L.","year":"2021","unstructured":"Puig L.; Bakulev A.L.; Kokhan M.M.; Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial. Dermatol Ther (Heidelb) 2021,11(4),1319-1332","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3899\/jrheum.141271","volume":"42","author":"Pavelka K.","year":"2015","unstructured":"Pavelka K.; Chon Y.; Newmark R.; Lin S.L.; Baumgartner S.; Erondu N.; A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J Rheumatol 2015,42(6),912-919","journal-title":"J Rheumatol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","volume":"188","author":"Busse W.W.","year":"2013","unstructured":"Busse W.W.; Holgate S.; Kerwin E.; Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013,188(11),1294-1302","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","volume":"370","author":"Mease P.J.","year":"2014","unstructured":"Mease P.J.; Genovese M.C.; Greenwald M.W.; Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014,370(24),2295-2306","journal-title":"N Engl J Med"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612829666230904150808","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/220689\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612829666230904150808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T08:37:04Z","timestamp":1704962224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/220689\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":126,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612829666230904150808","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}